The main factors responsible for the low efficacy include the heterogeneity of EGFR molecules and glioma tissues [10], complication of EGFR downstream signaling pathways [11], and difficulty of EGFR antagonists to pass through the BBB [12]. This evidence concerns the gene EGFR and glioma.